CN1212337C - 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 - Google Patents
肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 Download PDFInfo
- Publication number
- CN1212337C CN1212337C CN 02139537 CN02139537A CN1212337C CN 1212337 C CN1212337 C CN 1212337C CN 02139537 CN02139537 CN 02139537 CN 02139537 A CN02139537 A CN 02139537A CN 1212337 C CN1212337 C CN 1212337C
- Authority
- CN
- China
- Prior art keywords
- ifn
- tumor
- interferon
- ngr
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
肿瘤组织中 血清中 瘤中浓度只组别 IFNα浓度 IFNα浓度 /血清中浓度数pg/g pg/ml (%) |
NS组 4 0 0 |
普通干扰素组 5 0 298.6±52.3 0 |
靶向干扰素组 5 254.5±78.2 314.2±55.8 80.9 |
组别 | 只数 | 血清中IFNα2apg/ml | 瘤组织IFNα2apg/g | 肺组织IFNα2apg/g | 肝组织IFNα2apg/g |
NS组 | 4 | 0 | 0 | 0 | 50.1±4.2 |
普通干扰素组 | 4 | 46.5±8.9 | 50.8±4.5 | 70.8±20.7 | 48.5±7.1 |
靶向干扰素组 | 4 | 69.3±20.8 | 93.3±27.9 | 77.6±12.9 | 66.6±12.1 |
血清 | 肿瘤 | 肺 | 肝 | |
靶向组/普通组×100% | 149 | 183.7 | 109.6 | 137.3 |
组别 | 鼠数/只 | 治 疗 天 数 | ||||||||
0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 6 | 88.0±58.2 | 175.2±166.6 | 435.0±263.1 | 660.6±371.2 | 837.9±487.5 | 1103.5±551.9 | 1355.5±831.0 | 1870.0±886.0 | 2243.5±1155.4 |
普通IFN | ||||||||||
LH | 56 | 94.2±64.0 | 183.6±138.8 | 285.2±213.2 | 496.4±363.5 | 696.5±438.3 | 903.5±550.8 | 1267.9±602.6 | 1549.1±902.6 | 1594.1±525.8 |
85.6±44.2 | 70.4±19.4 | 101.9±40.3* | 176.3±49.3* | 286.3±124.9* | 324.7±151.8** | 324.8±127.3* | 549.6±181.0* | 614.6±260.8* | ||
靶向IFN | ||||||||||
L | 6 | 87.5±70.1 | 96.7±40.6 | 135.2±90.6* | 199.9±10.7* | 255.4±132.5* | 329.6±223.4**# | 520.3±381.5*# | 577.5±484.7*# | 900.8±471.9*# |
H | 6 | 87.4±27.7 | 86.8±71.2 | 99.1±38.4* | 169.5±40.7** | 208.7±100.1* | 239.6±117.0** | 285.7±168.7* | 393.4±278.0** | 492.7±342.1** |
组别 | 鼠数/只 | 治疗天数 | |||||||
4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 6 | - | - | - | - | - | - | - | - |
普通IFN | |||||||||
L | 5 | -4.8 | 34.4 | 24.9 | 16.9 | 18.1 | 6.46 | 17.2 | 28.9 |
H | 6 | 60.0 | 76.6 | 73.3 | 65.8 | 70.6 | 76.0 | 70.6 | 72.6 |
靶向IFN | |||||||||
L | 6 | 44.8 | 69.0 | 69.3 | 69.5 | 70.1 | 61.6 | 67.1 | 59.8 |
H | 6 | 50.5 | 77.2 | 74.3 | 75.1 | 78.3 | 78.9 | 79.0 | 78.0 |
组别 | 鼠数/只 | 治 疗 天 数 | ||||||||
0 | 4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 5 | 71.7±41.5 | 101.9±58.5 | 125.9±57.7 | 161.6±94.2 | 169.0±108.2 | 214.6±64.1 | 257.9±84.1 | 360.8±251.8 | 392.8±244.2 |
普通IFN | ||||||||||
L | 5 | 64.0±57.8 | 75.5±50.4 | 83.7±62.5 | 96.6±71.0 | 116.6±82.5 | 126.8±74.4 | 141.4±28.5 | 153.7±38.0 | 181.5±82.5 |
H | 5 | 68.3±54.8 | 79.5±60.4 | 84.4±67.0 | 84.4±40.1 | 86.4±38.5 | 86.9±51.3** | 92.2±70.0** | 116.0±94.5 | 94.4±89.8* |
靶向IFN | ||||||||||
L | 5 | 67.5±16.2 | 53.9±22.6 | 52.7±38.5* | 70.9±28.2 | 79.3±28.4 | 97.9±45.8* | 98.4±27.8**# | 93.8±33.9*# | 90.4±31.1*# |
H | 6 | 66.3±33.5 | 47.9±6.2* | 47.8±14.8* | 59.5±16.8* | 62.3±24.3* | 79.3±52.0** | 66.5±34.7** | 77.7±33.3 | 72.8±48.0* |
组别 | 鼠数/只 | 治疗天数 | |||||||
4 | 8 | 12 | 16 | 20 | 24 | 28 | 32 | ||
对照 | 5 | - | - | - | - | - | - | - | - |
普通IFN | |||||||||
L | 5 | 25.9 | 33.5 | 40.2 | 31.0 | 40.9 | 45.2 | 57.4 | 53.8 |
H | 5 | 22.0 | 33.0 | 47.8 | 48.9 | 59.5 | 64.2 | 67.8 | 76.0 |
靶向IFN | |||||||||
L | 5 | 47.7 | 58.1 | 56.1 | 53.1 | 54.3 | 61.8 | 74.0 | 77.0 |
H | 6 | 53.0 | 62.0 | 63.2 | 63.1 | 63.0 | 74.2 | 78.5 | 81.5 |
组别 | 鼠数/只 | 治 疗 天 数 | ||||
0 | 3 | 6 | 9 | 12 | ||
对照 | 7 | 262.3±117.8 | 826.9±243.1 | 1450.2±1036.3 | 2600.6±1477.1 | 3859.4±2316.0 |
普通IFN | ||||||
L | 7 | 232.7±86.3 | 680.1±155.0 | 969.0±665.0 | 1814.9±1171.8 | 3104.1±2026.0 |
M | 7 | 222.7±54.1 | 590.0±138.0* | 1067.2±307.4 | 1670.5±481.8 | 3330.9±1500.3 |
H | 7 | 224.5±71.0 | 514.4±241.8* | 977.8±309.6 | 2255.6±1320.7 | 3602.4±1933.1 |
靶向IFN | ||||||
L | 7 | 222.9±30.0 | 454.8±250.9* | 513.3±258.3* | 647.5±313.5** | 1126.9±269.5** |
M | 7 | 228.3±57.0 | 697.1±357.1 | 1243.4±734.0 | 2044.3±1066.7 | 1905.7±647.9 |
H | 7 | 231.0±116.8 | 493.1±294.6 | 928.2±353.1 | 1905.7±674.9 | 3754.2±1373.0 |
组别 | 鼠数/只 | |||||
0. | 3 | 6 | 9 | 12 | ||
对照 | 7 | - | - | - | - | - |
普通IFN | ||||||
L | 7 | 0 | 17.7 | 33.1 | 30.2 | 19.6 |
M | 7 | 0 | 28.6 | 26.4 | 35.8 | 13.7 |
H | 7 | 0 | 37.8 | 32.5 | 13.3 | 6.65 |
靶向IFN | ||||||
L | 7 | 0 | 45.0 | 64.6 | 75.1 | 70.8 |
M | 7 | 0 | 15.7 | 14.3 | 21.4 | 20.6 |
H | 7 | 0 | 40.4 | 36.0 | 26.7 | 2.72 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02139537 CN1212337C (zh) | 2002-11-21 | 2002-11-21 | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02139537 CN1212337C (zh) | 2002-11-21 | 2002-11-21 | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1429846A CN1429846A (zh) | 2003-07-16 |
CN1212337C true CN1212337C (zh) | 2005-07-27 |
Family
ID=4750127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02139537 Expired - Fee Related CN1212337C (zh) | 2002-11-21 | 2002-11-21 | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1212337C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100400664C (zh) * | 2005-09-06 | 2008-07-09 | 中国人民解放军第四军医大学 | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 |
CN100390202C (zh) * | 2005-11-21 | 2008-05-28 | 中国人民解放军第四军医大学 | 肿瘤新生血管特异性结合多肽与重组人Tum-5融合蛋白及其制备方法 |
US7906120B2 (en) * | 2006-11-21 | 2011-03-15 | Abbott Laboratories | Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) |
CN102286074B (zh) * | 2011-07-06 | 2013-09-11 | 苏州工业园区晨健抗体组药物开发有限公司 | 一种cd13靶向肽ngr及其应用 |
CN104479024A (zh) * | 2014-06-19 | 2015-04-01 | 中国人民解放军成都军区总医院 | 新型抗瘤融合肽及其用途 |
CN105296515B (zh) * | 2015-08-21 | 2018-11-06 | 四川大学华西医院 | 一种干扰素A2b与胶原结合结构域的融合蛋白及其制备方法和用途 |
-
2002
- 2002-11-21 CN CN 02139537 patent/CN1212337C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1429846A (zh) | 2003-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3825467B2 (ja) | インターロイキン―7を用いた選定免疫療法 | |
CN1173745C (zh) | 化学修饰的蛋氨酸酶及其在抗蛋氨酸和抗高半胱氨酸的化学治疗中的应用 | |
CN1939532A (zh) | 真菌免疫调节蛋白之用途 | |
CN1763093A (zh) | 含有hiv转导结构域的生存素突变体及制备方法和应用 | |
CN101080420A (zh) | 胸腺特异性蛋白质 | |
CN101045156A (zh) | 特异靶向性药物及其用途 | |
CN1284134A (zh) | 利用毕赤氏酵母表达系统生产抗生血管蛋白质∶制管张素,内抑制素或静息蛋白的方法 | |
CN1861634A (zh) | 犬干扰素α、制备方法和用途 | |
CN1142186A (zh) | 用白介素-10激活外周血单核细胞的细胞溶解活性 | |
CN1212337C (zh) | 肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备 | |
CN1243018C (zh) | 一种新的血管发生抑制剂 | |
CN1765932A (zh) | 一种胸腺素α1和干扰素的融合蛋白 | |
CN101058809A (zh) | 人源化改造的鼠ing4基因及其腺病毒表达载体 | |
CN1711099A (zh) | 具有抗肿瘤和抗毒活性的提取物 | |
CN1506051A (zh) | 薯蓣皂苷元的抗肿瘤新用途 | |
CN1309738C (zh) | 抗il-8单克隆抗体、其可变区序列及其应用 | |
CN1251677C (zh) | 一种以20(s)-原人参二醇为有效成分的抗癌辅助药物及应用 | |
CN1903373A (zh) | 一种表达trail蛋白质的大肠杆菌在制备肿瘤治疗药物中的用途 | |
CN1775947A (zh) | 能够表达肿瘤特异凋亡肽的重组腺病毒及制备方法和应用 | |
CN1233823C (zh) | 抗原致敏的人gm-csf基因修饰的人树突状细胞、其制法和用途 | |
CN1261372A (zh) | 天然抗肿瘤性或抗病毒性物质及其用途 | |
CN1887296A (zh) | 一种诱导抗肿瘤免疫的方法及其在制药中的应用 | |
CN101096384A (zh) | 一种抗肿瘤融合蛋白的制备方法及其应用 | |
CN1225481C (zh) | 一种重组抗肿瘤侵袭转移的融合蛋白 | |
CN1506375A (zh) | 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI KYRSHU SCIENCE & TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: THE FOURTH MILITARY MEDICAL UNIVERSITY OF P.L.A. Effective date: 20050107 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050107 Address after: 710075 New Era Hotel, 19 high tech Zone, Shaanxi, Xi'an Applicant after: Shaanxi Jiuzhou Technology Co.,Ltd. Address before: 710032 No. 17 West Changle Road, Shaanxi, Xi'an Applicant before: THE FOURTH MILITARY MEDICAL University |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANXI KYRSHU BIOLOGICAL MEDICINE SCIENCE + TECHNO Free format text: FORMER OWNER: SHANXI JIUZHOU BIOLOGY SCIENCE AND TECHNOLOGY CO., LTD. Effective date: 20091113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANXI JIUZHOU BIOLOGY SCIENCE AND TECHNOLOGY CO., Free format text: FORMER NAME: SHANXI KYRSHU SCIENCE CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: No. six, No. 196, science and technology zone, Xi'an hi tech Zone, Shaanxi Patentee after: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. Address before: 19 times hotel, new epoch zone, Xi'an hi tech Zone, Shaanxi Patentee before: Shaanxi Jiuzhou Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20091113 Address after: No. six, No. 196, science and technology zone, Xi'an hi tech Zone, Shaanxi Patentee after: Shanxi GeoBiopharma Corp. Address before: No. six, No. 196, science and technology zone, Xi'an hi tech Zone, Shaanxi Patentee before: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOMEDICINE PARK Effective date: 20130625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130625 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: Shanxi GeoBiopharma Corp. |
|
ASS | Succession or assignment of patent right |
Owner name: SHAANXI JIUZHOU BIOMEDICINE PARK Free format text: FORMER OWNER: SHAANXI JIUZHOU BIOTECHNOLOGY CO., LTD. Effective date: 20130805 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130805 Address after: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee after: Shanxi GeoBiopharma Corp. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: SHAANXI JIUZHOU BIOTECHNOLOGY Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160525 Address after: 403, room four, building 196, Kyushu science and Technology Park, No. six, 710065 hi tech Zone, Xi'an, Shaanxi Patentee after: SHAANXI SHENZHOU BIOTECHNOLOGY CO.,LTD. Address before: 710065 No. six, No. 196, hi tech Zone, Shaanxi, Xi'an Patentee before: Shanxi GeoBiopharma Corp. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050727 Termination date: 20181121 |
|
CF01 | Termination of patent right due to non-payment of annual fee |